For the first time, FDA has given approval of an oral treatment of patients with unresectable or metastatic non-squamous non-small cell lung cancer whose tumors have human epidermal growth factor receptor 2…
Tag: Lung Cancer News
World Lung Cancer Day: Combating the Problem of Late Detection
World Lung Cancer Day is observed on August 1 annually across the globe. It was first established in the year 2012 and is observed every year to raise awareness of lung cancer…
Lung Cancer Risk Factors in Adults with Interstitial Lung Disease
Interesting Lung Diseases (ILDs) are characterized by pathological changes in Pulmonary parenchyma. It is a group of conditions that cause inflammation in the lungs. This can be caused by medication, radiation therapy…
High-Dose Aumoltertinib for Untreated EGFR- Variant NSCLC
Aumoltertinib is a third-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and has achieved potent efficacy for advanced EGFR-mutated non-small cell lung cancer patients. Phase 2 non-randomized clinical trial was conducted at…
Study: New Nanoparticles Therapy for Lung Cancer Patients
A new research led by Gaurav Sahay of Oregon State University’s College ir Pharmacy was conducted in collaboration with Oregon Health & Science University and the University of Helsinki. In this study,…
Tarlatamab Shows Improved Overall Survival Over Chemotherapy in SCLC
Tarlatamab received accelerated approval for treatment of patients with previously treated small-cell lung cancer. It meaningfully improved overall survival compared with Chemotherapy in SCLC patients that progressed on or after initial platinum-based…
Predicting Lung Cancer Risk with AI based Deep Learning Model
New research has been presented during the American Thoracic Society 2025 International Conference. This new deep learning model was able to predict lung cancer risk by using low-dose CT screening exam. The…
FDA Grants Accelerated Approval to Telisotuzumab Vedotin-tllv for NSCLC
The FDA has granted accelerated approval to Telisotuzumab vedotin for the treatment of patients with locally advanced or metastatic, nonsquamous non-small cell lung cancer with high c-MET protein overexpression. This approval is…